Abstract The Canadian Cardiovascular Society (CCS) atrial fibrillation (AF) guidelines
program was developed to aid clinicians in the management of these complex patients, as …

Abstract Background Testing of factor Xa inhibitors for the prevention of cardiovascular
events in patients with rheumatic heart disease–associated atrial fibrillation has been …

Importance Acute coronary syndromes (ACS) are characterized by a sudden reduction in
blood supply to the heart and include ST-segment elevation myocardial infarction (STEMI) …

Intracranial atherosclerotic stenosis (ICAS) is one of the most frequent causes of stroke
worldwide and confers one of the greatest risks of recurrent stroke compared with other …

Background Evidence from a recent trial has shown that the antiinflammatory effects of
colchicine reduce the risk of cardiovascular events in patients with recent myocardial …

Health professionals are encouraged to take the Guidelines fully into account when
exercising their clinical judgment, as well as in the determination and the implementation of …

Health professionals are encouraged to take the ESC Guidelines fully into account when
exercising their clinical judgment, as well as in the determination and the implementation of …

Summary Background Asundexian (Bayer AG, Leverkusen, Germany), an oral small
molecule factor XIa (FXIa) inhibitor, might prevent thrombosis without increasing bleeding …

Background Patients with peripheral artery disease who have undergone lower-extremity
revascularization are at high risk for major adverse limb and cardiovascular events. The …

Coronavirus disease 2019 (COVID-19), currently a worldwide pandemic, is a viral illness
caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The …